279 related articles for article (PubMed ID: 25301037)
1. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.
Christensen H; Trotter CL; Hickman M; Edmunds WJ
BMJ; 2014 Oct; 349():g5725. PubMed ID: 25301037
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
[TBL] [Abstract][Full Text] [Related]
3. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
5. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
[TBL] [Abstract][Full Text] [Related]
6. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.
Tirani M; Meregaglia M; Melegaro A
PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805
[TBL] [Abstract][Full Text] [Related]
7. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
Christensen H; Hickman M; Edmunds WJ; Trotter CL
Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ
PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448
[TBL] [Abstract][Full Text] [Related]
9. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
Whittles LK; Didelot X; White PJ
Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
[TBL] [Abstract][Full Text] [Related]
10. Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England.
Christensen H; Trotter CL
Vaccine; 2017 Jan; 35(2):208-211. PubMed ID: 27923519
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study.
Arifin SMN; Zimmer C; Trotter C; Colombini A; Sidikou F; LaForce FM; Cohen T; Yaesoubi R
Med Decis Making; 2019 Jul; 39(5):553-567. PubMed ID: 31268405
[No Abstract] [Full Text] [Related]
12. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
Si S; Zomer E; Fletcher S; Lee J; Liew D
Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
[TBL] [Abstract][Full Text] [Related]
14. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.
Régnier SA; Huels J
Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
[TBL] [Abstract][Full Text] [Related]
16. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
Trotter CL; Edmunds WJ
BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry.
Chung GS; Hutton DW
PLoS One; 2020; 15(10):e0239926. PubMed ID: 33035260
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
